Inhaler Adherence in Severe Unstable Asthma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

220 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-12-31

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators hypothesize that aligning digital data on PEF and adherence with the patient's own clinical course achieves better asthma control and identifies risks for future loss of control, compared to current best practice. The study has an adherence optimisation phase, week 1-12 followed by a medication management phase, week 12 to week 32.

The investigators will compare two asthma education interventions, standard Guideline recommended practice and feedback from the individual's own INCA device, which assesses inhaler adherence and relates adherence with changes in PEF and symptom scores over time.

The study has two co-primary endpoints, one will be a comparison of the adherence to therapy and the other will be a comparison of the appropriateness of medication prescriptions between the two study groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Study of the Feedback From an Adherence Monitor on Asthma Control

NCT01529697

Asthma

COMPLETED NA

A Study of Inhaler Use in the Community

NCT02552472

Asthma Chronic Obstructive Pulmonary Disease Airways Disease

COMPLETED

Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers

NCT05111262

Asthma Nonadherence, Medication

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Comparison of Two Medication Adherence Strategies to Improve Asthma Treatment Adherence

NCT00115323

Asthma Lung Diseases

COMPLETED NA

Teaching Inhaler Use With the INCA Device in a Community Pharmacy Setting

NCT02203266

Asthma Pulmonary Disease, Chronic Obstructive

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators hypothesize that aligning adherence, inhaler technique and digitally recorded PEF to inform patients and as the basis of prescribing decisions achieves better inhaler adherence and technique and also allows physicians to make appropriate prescribing decisions, compared to current best practice.

The investigators will compare two asthma education interventions, standard BTS/SIGN Guideline recommended practice and feedback from the individual's own INCA device, which assesses inhaler adherence and relates adherence with changes in PEF and symptom scores over time.

This education phase is followed by a medication optimisation phase (weeks 12-32) in which there are 3 cycles of medication optimisation guided by a digital script. The script either adjusts the medications following the GINA recommendation or uses the GINA recommendation but is supplemented with data on adherence and PEF that are recorded to digital, time-stamped, recording devices.

The aim of the study is to improve and maintain adherence to preventer therapy, so that medication and other costs as well as the quality of life, exacerbation rates are optimal.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Routine inhaler adherence care

Normal Care group This management is based on the inhaler training recommendations of the BTS/SIGN group (http://www.brit-thoracic.org.uk/Portals/0/Guidelines/AsthmaGuidelines/sign101%20Jan%202012.pdf) and medication management of the GINA management strategy.

The core features of the "usual care" group are:

1. The patient's inhaler technique will be checked using a checklist, at each visit. If there are errors these will be corrected using teach-to-goal principals.
2. Adherence will be discussed and barriers to adherence addressed, using motivational interview techniques.
3. Written action plans for managing asthma, based on changes in PEF and symptoms will be given.
4. In follow up, medication changes in response to the above will be directed by these, as suggested by GINA management guidelines using a standardised digital script.

Group Type PLACEBO_COMPARATOR

Usual Care

Intervention Type BEHAVIORAL

The core features of the "usual care" group are:

The patient's inhaler technique will be checked using a checklist, at each visit. If there are errors these will be corrected using teach-to-goal principals.

Adherence will be discussed and barriers to adherence addressed, using motivational interview techniques.

Written action plans for managing asthma, based on changes in PEF and symptoms will be given.

In follow up, medication changes in response to the above will be directed by these, as suggested by Guidelines.

INCA feedback

1. The patient's treatment goal is established and used as the focus of the conversation.
2. Data from the INCA device including (1) time of use, (2) handling proficiency and (3) inhalation flow rates are discussed, with three graphs as shown in the appendix and derived as discussed. These are aimed to enhance the value of the inhaler.
3. Data from the electronic PEF and AQLQ are correlated with digitally recorded adherence so that these can be used to account for improvements or declines in these measures.
4. In follow up, medication changes in response to the above (adherence, PEF, ACT and exacerbations) are made using a standardised digital script.

Group Type ACTIVE_COMPARATOR

INCA feedback

Intervention Type BEHAVIORAL

The study team have developed a device which is attached to inhalers that makes an audio recording of the inhaler being used. Analysis of this audio data provides objective evidence of the time of inhaler use, technique of use and the peak inspiratory flow the patient makes each time they use their inhaler. Our preliminary experiences with the information obtained from this device indicate that adherence is poor in patients with severe asthma due to any one the following issues poor time of use, errors in handling and low peak inspiratory flow rates.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

INCA feedback

The study team have developed a device which is attached to inhalers that makes an audio recording of the inhaler being used. Analysis of this audio data provides objective evidence of the time of inhaler use, technique of use and the peak inspiratory flow the patient makes each time they use their inhaler. Our preliminary experiences with the information obtained from this device indicate that adherence is poor in patients with severe asthma due to any one the following issues poor time of use, errors in handling and low peak inspiratory flow rates.

Intervention Type BEHAVIORAL

Usual Care

The core features of the "usual care" group are:

The patient's inhaler technique will be checked using a checklist, at each visit. If there are errors these will be corrected using teach-to-goal principals.

Adherence will be discussed and barriers to adherence addressed, using motivational interview techniques.

Written action plans for managing asthma, based on changes in PEF and symptoms will be given.

In follow up, medication changes in response to the above will be directed by these, as suggested by Guidelines.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must be willing to give voluntary informed consent
* Must have a clinical diagnosis of asthma supported by objective measures, one of the following by FEV1/FVC \<70% and FEV1 \<80% or - a 12% change in FEV1 following administration of a beta-agonist or spontaneously over 1 year period, a positive bronchial provocation test, or a 10% variability in PEF within a 7 day period.
* Must have a bronchodilator FEV1 \> 40% and \<80% in the past 1 year
* Current unstable asthma i.e. ACT score ≤ 19 at enrolment despite already being managed with GINA step 3-5 therapy.
* One or more courses of oral corticosteroids in the prior year, or a hospitalization or ED attendance with an asthma exacerbation in the last year
* Age 18 years or older at time of consent.
* Capable of understanding and complying with the requirements of the protocol, including the ability to attend for all required visits.
* Able and willing to take inhaled medication via a Diskus.
* In the opinion of the investigator suitable for use of a salmeterol/fluticasone Diskus inhaler or already using a salmeterol/fluticasone inhaler.

Exclusion Criteria

* Have used any investigational product or device within 3 months of the enrolment visit.
* Have known previous sensitivity to Seretide (salmeterol/fluticasone).
* Have a known significant (in the opinion of the investigator) concurrent medical disease, pregnancy that might mean that the participant cannot complete the study.
* Be taking omalizumab or other biological agent used in the treatment of asthma
* Concurrent treatment with potent cytochrome P450 3A4 (CYP3A4) inhibitors; Ketoconazole and Ritonavir.

* Current smokers and ex-smokers with a greater than 20 pack year history of cigarette smoke

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No